Scott Andrew Smith - Net Worth and Insider Trading

Scott Andrew Smith Net Worth

The estimated net worth of Scott Andrew Smith is at least $1 Million dollars as of 2024-04-27. Scott Andrew Smith is the President of BioAtla Inc and owns about 345,656 shares of BioAtla Inc (BCAB) stock worth over $877,966. Scott Andrew Smith is the See Remarks of Celgene Corp and owns about 2,325 shares of Celgene Corp (CELG) stock worth over $251,658. Scott Andrew Smith is also the Director of Spring Bank Pharmaceuticals Inc and owns about 3,471 shares of Spring Bank Pharmaceuticals Inc (SBPH) stock worth over $16,800. Details can be seen in Scott Andrew Smith's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Scott Andrew Smith has not made any transactions after 2021-12-02 and currently still holds the listed stock(s).

Transaction Summary of Scott Andrew Smith

To

Scott Andrew Smith Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Scott Andrew Smith owns 7 companies in total, including Spring Bank Pharmaceuticals Inc (SBPH) , Titan Pharmaceuticals Inc (TTNP) , and F-star Therapeutics Inc (FSTX) among others .

Click here to see the complete history of Scott Andrew Smith’s form 4 insider trades.

Insider Ownership Summary of Scott Andrew Smith

Ticker Comapny Transaction Date Type of Owner
SBPH Spring Bank Pharmaceuticals Inc 2020-06-24 director
TTNP Titan Pharmaceuticals Inc 2017-01-02 director
FSTX F-star Therapeutics Inc 2018-08-15 director
BCAB BioAtla Inc 2021-12-02 director & President
APGN Apexigen Inc 2022-07-29 director
VTRS Viatris Inc 2022-12-29 director
BCACU Brookline Capital Acquisition Corp 2022-07-29 director

Scott Andrew Smith Latest Holdings Summary

Scott Andrew Smith currently owns a total of 3 stocks. Among these stocks, Scott Andrew Smith owns 345,656 shares of BioAtla Inc (BCAB) as of December 2, 2021, with a value of $877,966 and a weighting of 76.58%. Scott Andrew Smith owns 2,325 shares of Celgene Corp (CELG) as of August 1, 2014, with a value of $251,658 and a weighting of 21.95%. Scott Andrew Smith also owns 3,471 shares of Spring Bank Pharmaceuticals Inc (SBPH) as of June 28, 2019, with a value of $16,800 and a weighting of 1.47%.

Latest Holdings of Scott Andrew Smith

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
BCAB BioAtla Inc 2021-12-02 345,656 2.54 877,966
CELG Celgene Corp 2014-08-01 2,325 108.24 251,658
SBPH Spring Bank Pharmaceuticals Inc 2019-06-28 3,471 4.84 16,800

Holding Weightings of Scott Andrew Smith


Scott Andrew Smith Form 4 Trading Tracker

According to the SEC Form 4 filings, Scott Andrew Smith has made a total of 5 transactions in BioAtla Inc (BCAB) over the past 5 years, including 0 buys and 5 sells. The most-recent trade in BioAtla Inc is the sale of 4,090 shares on December 2, 2021, which brought Scott Andrew Smith around $91,084.

According to the SEC Form 4 filings, Scott Andrew Smith has made a total of 0 transactions in Celgene Corp (CELG) over the past 5 years. The most-recent trade in Celgene Corp is the sale of 0 shares on August 1, 2014, which brought Scott Andrew Smith around $0.

According to the SEC Form 4 filings, Scott Andrew Smith has made a total of 1 transactions in Spring Bank Pharmaceuticals Inc (SBPH) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Spring Bank Pharmaceuticals Inc is the acquisition of 3,000 shares on June 28, 2019, which cost Scott Andrew Smith around $49,080.

Insider Trading History of Scott Andrew Smith

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Scott Andrew Smith Trading Performance

GuruFocus tracks the stock performance after each of Scott Andrew Smith's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Scott Andrew Smith is -15.18%. GuruFocus also compares Scott Andrew Smith's trading performance to market benchmark return within the same time period. The performance of stocks bought by Scott Andrew Smith within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Scott Andrew Smith's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Scott Andrew Smith

Average Return

-58.54%

Average return per transaction

Outperforming Transactions

0%

0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 20.6 -15.18 -65.72 -58.54
Relative Return to S&P 500(%) 17.74 -15.86 -75.86 -60.83

Scott Andrew Smith Ownership Network

Ownership Network List of Scott Andrew Smith

No Data

Ownership Network Relation of Scott Andrew Smith


Scott Andrew Smith Owned Company Details

What does Spring Bank Pharmaceuticals Inc do?

Who are the key executives at Spring Bank Pharmaceuticals Inc?

Scott Andrew Smith is the director of Spring Bank Pharmaceuticals Inc. Other key executives at Spring Bank Pharmaceuticals Inc include VP of Finance and Treasurer Lori Firmani , director & President and CEO Martin J Driscoll , and Chief Scientific Officer Radhakrishnan P. Iyer .

Spring Bank Pharmaceuticals Inc (SBPH) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Spring Bank Pharmaceuticals Inc (SBPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Spring Bank Pharmaceuticals Inc (SBPH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Spring Bank Pharmaceuticals Inc (SBPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Spring Bank Pharmaceuticals Inc Insider Transactions

No Available Data

Scott Andrew Smith Mailing Address

Above is the net worth, insider trading, and ownership report for Scott Andrew Smith. You might contact Scott Andrew Smith via mailing address: C/o Celgene Corporation, 86 Morris Avenue, Summit Nj 07901.

Discussions on Scott Andrew Smith

No discussions yet.